Skip to content
PubMed This is a summary of 46 peer-reviewed journal articles Updated

Apparent Mineralocorticoid Excess: A Patient Guide

At a Glance

Apparent mineralocorticoid excess is a rare condition in which cortisol falsely activates the kidneys’ salt-retaining signals, causing high blood pressure, salt and water retention, and low potassium. Treatment combines receptor-blocking medicines, potassium, a low-sodium diet, and monitoring.

Apparent Mineralocorticoid Excess (AME) is a rare condition that fundamentally changes how the kidneys manage the delicate balance of salt and potassium. In a typical body, an enzyme called 11β-HSD2 acts as a protective filter in the kidneys, preventing the stress hormone cortisol from activating the body’s “salt-saving” receptors. In people with AME, this enzyme is either deficient or temporarily inhibited, allowing cortisol to reach those receptors and trick the body into behaving as though it has an excess of the salt-retaining hormone aldosterone [1][2].

The result of this biological “case of mistaken identity” is that the kidneys aggressively hold onto sodium and water while simultaneously losing too much potassium. This imbalance leads to the hallmark features of the condition: severe high blood pressure and low potassium levels that often appear early in childhood, though milder forms can present later. Because the body is under constant pressure from these signals, patients may experience challenges with growth and energy levels, though these often improve significantly once the right management plan is in place [3][4].

Living with AME requires a focused, lifelong approach to care that centers on three main pillars: medication, diet, and consistent monitoring. Specialists use medications called mineralocorticoid receptor antagonists to block the kidney’s receptors from the false signals from cortisol. This is paired with potassium supplements to replace what the kidneys lose and a low-sodium diet to reduce the workload on the heart and kidneys. While the condition is complex, these treatments are effective at controlling blood pressure and protecting long-term organ health [5][6].

While the journey of managing a rare diagnosis can feel overwhelming, it is important to remember that AME is a manageable condition. With a dedicated care team and modern treatment strategies, patients with AME can thrive, meet their developmental milestones, and lead full, active lives. Your role is to be the steady anchor in this process, ensuring that the daily balance of salt and hormones is maintained so you or your child can focus on living well [7][8].

Common questions in this guide

What causes apparent mineralocorticoid excess?
In AME, a kidney enzyme that normally keeps cortisol away from salt-regulating receptors is missing or temporarily blocked. Cortisol can then trigger those receptors, causing the kidneys to retain too much salt and water and lose potassium.
What symptoms does AME cause?
The main features are severe high blood pressure and low potassium, often starting in early childhood. Some people also have low energy or growth challenges, which may improve when treatment controls the condition.
How is apparent mineralocorticoid excess treated?
Treatment commonly combines medicines that block the kidney receptors activated by cortisol, potassium supplements, and a low-sodium diet. Regular monitoring helps the care team adjust treatment and protect the heart and kidneys.
Will AME require lifelong care?
AME usually needs ongoing, lifelong attention because the kidney’s salt-and-potassium imbalance can persist. With a consistent plan for medicine, diet, and monitoring, treatment can control blood pressure and support long-term health.
Can a child with AME grow and live an active life?
With effective management, children with AME can improve growth and energy, meet developmental milestones, and lead full, active lives. The care plan should be individualized by the child’s dedicated medical team.
How can families stay organized while managing AME?
Families can identify a primary coordinator for the multidisciplinary care team and keep medical records and genetic testing results together for appointments. Asking about dietary support and monitoring resources can also make daily care easier.

Get notified when new evidence is published on Apparent mineralocorticoid excess.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    The Dehydrogenase Hypothesis.

    Woods C, Tomlinson JW

    Advances in experimental medicine and biology 2015; (872()):353-80 doi:10.1007/978-1-4939-2895-8_16.

    PMID: 26216003
  2. 2

    Alterations of Cortisol Metabolism in Human Disorders.

    White PC

    Hormone research in paediatrics 2018; (89(5)):320-330 doi:10.1159/000485508.

    PMID: 29843121
  3. 3

    Apparent mineralocorticoid excess mimicking Bartter syndrome in infancy.

    Hatipoğlu S, Yıldırım E, Şalbaş ÖY, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2026; doi:10.1515/jpem-2026-0333.

    PMID: 42912472
  4. 4

    Apparent mineralocorticoid excess: comprehensive overview of molecular genetics.

    Lu YT, Zhang D, Zhang QY, et al.

    Journal of translational medicine 2022; (20(1)):500 doi:10.1186/s12967-022-03698-9.

    PMID: 36329487
  5. 5

    Case report: Clinical characteristics and Genetical analysis of HSD11B2 in three Chinese children with apparent mineralocorticoid excess: a case series.

    Ding Y, Cheng M, Cao B, et al.

    Frontiers in endocrinology 2024; (15()):1491825 doi:10.3389/fendo.2024.1491825.

    PMID: 39931437
  6. 6

    Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.

    Razzaghy-Azar M, Yau M, Khattab A, New MI

    The Journal of steroid biochemistry and molecular biology 2017; (165(Pt A)):145-150 doi:10.1016/j.jsbmb.2016.02.014.

    PMID: 26892095
  7. 7

    Apparent mineralocorticoid excess in Israel: a case series and literature review.

    Lebel A, Ben Shalom E, Mokatern R, et al.

    European journal of endocrinology 2024; (190(5)):347-353 doi:10.1093/ejendo/lvae049.

    PMID: 38652803
  8. 8

    Apparent mineralocorticoid excess with a novel HSD11B2 variant: longitudinal clinical and biochemical follow-Up.

    Nalluri BT, Kudugunti N, Sahay RK

    JCEM case reports 2026; (4(6)):luag083 doi:10.1210/jcemcr/luag083.

    PMID: 42064719

This page explains apparent mineralocorticoid excess for informational purposes only and does not constitute medical advice. Work with your healthcare team to individualize medicines, potassium, diet, and monitoring for you or your child.